Precigen, Inc.

Symbol: PGEN

NASDAQ

1.41

USD

Market price today

  • 31.1425

    P/E Ratio

  • 3.6926

    PEG Ratio

  • 350.98M

    MRK Cap

  • 0.00%

    DIV Yield

Precigen, Inc. (PGEN) Stock Price & Analysis

Shares Outstanding

248.92M

Gross Profit Margin

0.66%

Operating Profit Margin

-3.51%

Net Profit Margin

0.52%

Return on Assets

0.07%

Return on Equity

0.07%

Return on Capital Employed

-0.59%

Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Dr. Helen Sabzevari MPH, Ph.D.
Full-time employees:202
City:Germantown
Address:20374 Seneca Meadows Parkway
IPO:2013-08-08
CIK:0001356090

Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Ares Trading S.A.; Oragenics, Inc.; Castle Creek Biosciences, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.

General Outlook

In simple terms, Precigen, Inc. has 248.919 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 0.660% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -3.507%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 0.523%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust 0.075% return, is a testament to Precigen, Inc.'s adeptness in optimizing resource deployment. Precigen, Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.073%. Furthermore, the proficiency of Precigen, Inc. in capital utilization is underscored by a remarkable -0.591% return on capital employed.

Stock Prices

Precigen, Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $1.49, while its low point bottomed out at $1.42. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Precigen, Inc.'s stock market.

Liquidity Ratios

Analyzing PGEN liquidity ratios reveals its financial health of the firm. The current ratio of 299.13% gauges short-term asset coverage for liabilities. The quick ratio (280.31%) assesses immediate liquidity, while the cash ratio (32.97%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio299.13%
Quick Ratio280.31%
Cash Ratio32.97%

Profitability Ratios

PGEN profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -390.65% underscores its earnings before tax deductions. The effective tax rate stands at 113.38%, revealing its tax efficiency. The net income per EBT, -13.38%, and the EBT per EBIT, 111.40%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -350.66%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin-390.65%
Effective Tax Rate113.38%
Net Income per EBT-13.38%
EBT per EBIT111.40%
EBIT per Revenue-350.66%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 2.99, it details the span from stock purchase to revenue. The 3 days it takes to settle debts showcases its creditor relations.

cards.indicatorcards.value
Days of Sales Outstanding280
Operating Cycle26.65
Days of Payables Outstanding86
Cash Conversion Cycle-59
Receivables Turnover13.69
Payables Turnover4.25
Inventory Turnover7328000.00
Fixed Asset Turnover1.52
Asset Turnover0.14

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, -0.27, and free cash flow per share, -0.28, depict cash generation on a per-share basis. The cash per share value, 0.25, showcases liquidity position. Lastly, the operating cash flow sales ratio, -3.10, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share-0.27
Free Cash Flow per Share-0.28
Cash per Share0.25
Operating Cash Flow Sales Ratio-3.10
Free Cash Flow to Operating Cash Flow Ratio1.02
Cash Flow Coverage Ratio-9.43
Short Term Coverage Ratio-55.68
Capital Expenditure Coverage Ratio-43.57
Dividend Paid and Capex Coverage Ratio-43.57

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 4.70%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.06, we discern the balance between debt and equity financing. The long-term debt to capitalization, 4.74%, and total debt to capitalization, 5.65%, ratios shed light on its capital structure. An interest coverage of -161.60 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio4.70%
Debt Equity Ratio0.06
Long Term Debt to Capitalization4.74%
Total Debt to Capitalization5.65%
Interest Coverage-161.60
Cash Flow to Debt Ratio-9.43
Company Equity Multiplier1.27

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 0.03, provides a glimpse into top-line earnings distributed across each share. Net income per share, -0.39, reflects the portion of profit attributed to each share. The book value per share, 0.48, represents the net asset value distributed per share, while the tangible book value per share, 0.17, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share0.03
Net Income Per Share-0.39
Book Value Per Share0.48
Tangible Book Value Per Share0.17
Shareholders Equity Per Share0.48
Interest Debt Per Share0.03
Capex Per Share-0.01

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, -76.87%, indicates top-line expansion, while the gross profit growth, -123.05%, reveals profitability trends. EBIT growth, -19.19%, and operating income growth, -19.19%, offer insights into operational profitability progression. The net income growth, -20.22%, showcases bottom-line expansion, and the EPS growth, 2.50%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth-76.87%
Gross Profit Growth-123.05%
EBIT Growth-19.19%
Operating Income Growth-19.19%
Net Income Growth-20.22%
EPS Growth2.50%
EPS Diluted Growth2.50%
Weighted Average Shares Growth22.05%
Weighted Average Shares Diluted Growth22.05%
Operating Cash Flow Growth-2.90%
Free Cash Flow Growth2.15%
10-Year Revenue Growth per Share-95.61%
5-Year Revenue Growth per Share-97.95%
3-Year Revenue Growth per Share-95.88%
10-Year Operating CF Growth per Share79.12%
5-Year Operating CF Growth per Share71.47%
3-Year Operating CF Growth per Share40.63%
10-Year Net Income Growth per Share58.80%
5-Year Net Income Growth per Share90.03%
3-Year Net Income Growth per Share36.86%
10-Year Shareholders Equity Growth per Share-94.59%
5-Year Shareholders Equity Growth per Share-82.70%
3-Year Shareholders Equity Growth per Share20.52%
10-Year Dividend per Share Growth per Share-100.00%
Receivables Growth-88.59%
Inventory Growth-100.00%
Asset Growth-30.07%
Book Value per Share Growth-23.10%
Debt Growth-86.20%
R&D Expense Growth3.06%
SGA Expenses Growth-25.91%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 327,197,536.14, captures the company's total value, considering both debt and equity. Income quality, 0.70, assesses the reliability of reported earnings. The ratio of intangibles to total assets, 44.57%, indicates the value of non-physical assets, and capex to operating cash flow, 2.29%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value327,197,536.14
Income Quality0.70
Research and Development to Revenue780.95%
Intangibles to Total Assets44.57%
Capex to Operating Cash Flow2.29%
Capex to Revenue-24.67%
Capex to Depreciation-23.04%
Stock-Based Compensation to Revenue158.84%
Graham Number2.07
Return on Tangible Assets-114.54%
Graham Net Net0.09
Working Capital45,770,000
Tangible Asset Value42,086,000
Net Current Asset Value27,111,000
Average Receivables7,689,500
Average Payables2,897,000
Average Inventory143,500.5
Days Sales Outstanding92
Days Payables Outstanding57
ROIC-70.46%
ROE-0.81%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 2.96, and the price to book ratio, 2.96, reflect the market's valuation relative to the company's book value. The price to sales ratio, 16.27, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -5.13, and price to operating cash flows, -5.24, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio2.96
Price to Book Ratio2.96
Price to Sales Ratio16.27
Price Cash Flow Ratio-5.24
Price Earnings to Growth Ratio3.69
Enterprise Value Multiple-4.99
Price Fair Value2.96
Price to Operating Cash Flow Ratio-5.24
Price to Free Cash Flows Ratio-5.13
Price to Tangible Book Ratio2.77
Enterprise Value to Sales52.56
Enterprise Value Over EBITDA-3.98
EV to Operating Cash Flow-4.89
Earnings Yield-29.27%
Free Cash Flow Yield-20.89%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Precigen, Inc. (PGEN) on the NASDAQ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is 31.142 in 2024.

What is the ticker symbol of Precigen, Inc. stock?

The ticker symbol of Precigen, Inc. stock is PGEN.

What is company IPO date?

IPO date of Precigen, Inc. is 2013-08-08.

What is company current share price?

Current share price is 1.410 USD.

What is stock market cap today?

The market cap of stock today is 350975790.000.

What is PEG ratio in 2024?

The current 3.693 is 3.693 in 2024.

What is the number of employees in 2024?

In 2024 the company has 202.